Mesenchymal stem cells (MSCs) are a heterogeneous population of multipotent cells that are capable of differentiating into osteocytes, chondrocytes and adipocytes. Recently, MSCs have been found to home to the tumour site and engraft in the tumour stroma. However, it is not yet known whether they have a tumour promoting or suppressive function. We investigated the interaction between prostate cancer cell lines 22Rv1, DU145 and PC3, and bone marrow-derived MSCs. MSCs were 'educated' for extended periods in prostate cancer cell conditioned media and PC3-educated MSCs were found to be the most responsive with a secretory profile rich in pro-inflammatory cytokines. PC3-educated MSCs secreted increased osteopontin (OPN), interleukin-8 (IL-8) and fibroblast growth factor-2 (FGF-2) and decreased soluble fms-like tyrosine kinase-1 (sFlt-1) compared to untreated MSCs. PC3-educated MSCs showed a reduced migration and proliferation capacity that was dependent on exposure to PC3-conditioned medium. Vimentin and a-smooth muscle actin (aSMA) expression was decreased in PC3-educated MSCs compared to untreated MSCs. PC3 and DU145 education of healthy donor and prostate cancer patient-derived MSCs led to a reduced proportion of FAP1 aSMA1 cells contrary to characteristics commonly associated with cancer associated fibroblasts (CAFs). The migration of PC3 cells was increased toward both PC3-educated and DU145-educated MSCs compared to untreated MSCs, while DU145 migration was only enhanced toward patient-derived MSCs. In summary, MSCs developed an altered phenotype in response to prostate cancer conditioned medium which resulted in increased secretion of pro-inflammatory cytokines, modified functional activity and the chemoattraction of prostate cancer cells.
Introduction
Prostate cancer (PCa) is the fourth most common cancer worldwide and the second most common cancer diagnosed in men. An estimated 307,000 deaths were recorded globally in 2012, with incidence rates found to be higher in Western and Northern Europe, North America and Oceania. 1 While
PCa can metastasise to tissues such as the lung, liver, pleura and adrenals, the most frequent site of metastasis is the bone. 2 Currently, there are no curative therapies available for metastatic PCa. The likelihood of a cancer cell reaching and invading the bone depends on its ability to pass through the endothelium, migrate through the circulatory system and extravasate from the blood vessel to the metastatic site. 3 It is now understood that tumour cells interact with cells of the surrounding stroma in a manner that drives tumour progression. The tumour microenvironment is a chronic site of inflammation, 4 where tumour cells release pro-inflammatory cytokines and chemokines that attract innate immune cells as well as mesenchymal stem cells (MSCs) 5 to the tumour which in turn releases factors that activate the immune system. This cytokine rich milieu stimulates growth of the tumour and its invasive capacity. 5 MSCs are multipotent cells that reside in various areas such as the bone marrow, fat and dental pulp. MSCs have multiple functions within the body. Several studies have reported the migration of MSCs to the heart following myocardial infarction, as well as the lungs, 6 liver 7 and brain 8 during injury. This migratory function allows MSCs to home to injured tissue and contribute to repair. Although the mechanisms are not fully understood, there is evidence to suggest that MSCs are stimulated to migrate to these tissues through the release of cytokines and chemokines present in the inflammatory sites that bind to their corresponding receptors on the MSCs. 6, 8 It is now apparent that the tumour microenvironment, also a site of inflammation, stimulates the homing of MSCs to the primary site whereby they form part of the stroma. 5 Recent studies have shown a role for MSCs in tumour promotion and although the mechanisms are not yet clear, they have been found to release and respond to cytokines at the tumour site. [9] [10] [11] In addition, tumour growth relies on new blood capillary formation and MSCs have been suggested to contribute to neovascularisation through the secretion of growth factors including vascular endothelial growth factor (VEGF). 12, 13 The aim of our study was to investigate the impact of long-term exposure of MSCs to PCa cells on MSC function and phenotype, and their reciprocal impact on PCa cells. We developed an in vitro experimental system to examine the response of human bone marrow-derived MSCs to long-term growth in PCa cell conditioned media (CM). We compared the impact of non-metastatic 22Rv1 CM, to the brain metastatic DU145 and the bone metastatic PC3 CM on healthy donor MSCs. The resulting MSCs were examined for molecular and functional phenotypic changes caused by the conditioning. We further confirmed the relevance of our findings in novel metastatic PCa patient-derived MSCs. Our results demonstrate that metastatic PCa CM enhances cytokine secretion from MSCs, and decreases their proliferative and migratory potential in a reversible manner. Furthermore, the resultant conditioned MSCs, act as attractants increasing the rate of PCa cell invasion.
Methods

Cell culture
Male human bone marrow aspirates were obtained from the iliac crests of healthy volunteers and metastatic PCa patients after informed consent and under ethical approval (Healthy donors: Galway University Hospitals and the National University of Ireland Galway Research Ethics Committees; PCa patients: St. Vincent's Hospital and Cancer Trials Ireland [ICORG Protocol 14-04]). MSCs were isolated from the bone marrow aspirates and separated using Percoll density centrifugation (1.073 g/mL; Gibco, Biosciences, Dublin, Ireland). Non-adherent hematopoietic cells were depleted following 10-12 days of culture. MSC capacity to differentiate into osteocytes, chondrocytes and adipocytes, positive expression of cell surface markers (CD105, CD73, CD90) and negative expression of hematopoietic markers (CD34, CD45 and HLA-DR) was confirmed. The healthy donor MSCs used in our study were isolated from male donors aged 38 (donor 1), 25 (donor 2), 20 (donor 3), 26 (donor 4) and 25 (donor 5). Patient-derived MSCs were from metastatic PCa patients aged 62 (PCa1), 82 (PCa2) and 65 (PCa3). MSCs were used experimentally up to passage 7. Human PCa cell lines LnCAP, PC3, DU145 and 22Rv1 were obtained from the American tissue culture collection (ATCC, Manassas, VA). Short tandem repeat (STR) profiling was performed to verify the cell lines (LGC Standards, Teddington, UK). All cells were cultured in aMinimum Essential Medium GlutaMAX TM (Thermo Fisher, Dublin, Ireland) supplemented with serotyped 10% FBS and 100 units/mL of penicillin, 100 lg/mL of streptomycin and 0.25 lg/mL of FungizoneV R Antimycotic (Thermo Fisher). MSC culture medium was supplemented with 1 ng/mL fibroblast growth factor-2 (FGF2) (Peprotech, London, UK). MSC growth in tumour cell conditioned media PC3, DU145 and 22Rv1 cells were grown for 48 hr at 378C with 5% CO 2 until they were 60-70% confluent. The resulting CM was centrifuged at 300g and the supernatant was filtered through a 0.45 lm pore syringe filter (Whatman, Maidstone, UK). The CM was frozen at 2208C and used within 30 days. The MSCs were grown throughout the conditioning period in a 1:1 ratio of complete and PC3, DU145 or 22Rv1 CM supplemented with 1 ng/mL FGF2. For withdrawal experiments, MSCs grown for a further 12-16 days in complete medium prior to experimental use. Cytokine and growth factor quantification was performed after the relevant period of conditioning: cells were trypsinised and re-seeded at 5 3 10 4 cells per mL in 10 mL into a Petri dish for 24 hr, media collected, and centrifuged for 10 min at 300g, and then frozen at 2808C until use.
Cytokine and growth factor screening and quantification using proteome profilers and mesoscale discovery platform 
Immunofluorescence staining
Cells were fixed for 20 min in 10% formalin (Thermo Fisher) and permeabilised in D-PBS-Triton X-100 (0.1%). The cells were blocked in 1% BSA in D-PBS and incubated with 1:500 anti-aSMA mouse monoclonal antibody, 1:500 anti-vimentin rabbit monoclonal antibody, 1:200 anti-FSP1 rabbit polyclonal antibody or 1:300 anti-FAP mouse monoclonal antibody. Cells were incubated with secondary antibody (AlexaFluor 488 goat anti-mouse IgG or Alexa FluorV R 594 goat anti-rabbit IgG, Invitrogen, Dublin, Ireland) and stained with DAPI (Sigma). The plates were scanned and images taken using the Operetta HTS imaging system (PerkinElmer, Dublin, Ireland) at 203 magnification.
Cell migration, proliferation assays and flow cytometry
See supplementary section for details.
Statistical analysis
Statistical analyses were performed with GraphPad Prism software 6.0 (GraphPad Software, La Jolla, CA). Error bars represent the standard deviation (SD) and were calculated using GraphPad Prism. Specific statistical tests used were the unpaired Student's t-test or ANOVA with Bonferroni's correction, and all p-values <0.05 were considered statistically significant.
Results
Increased secretion of pro-inflammatory cytokines in PCaeducated MSCs
To understand what impact PCa cells can have on the secretory profile of MSCs during tumour progression, we investigated the effects of long-term exposure to the secretome derived from PCa cells on MSCs from healthy human males. To this end, we examined the secretory changes that occur in MSCs that were educated in PC3 (bone metastatic AR-negative), DU145 (brain metastatic AR-negative) and 22Rv1 (non-metastatic AR-positive) CM for 20 days. Metastatic DU145 and PC3-educated MSCs were found to be more active in pro-inflammatory cytokine production (Figs. 1a and 1b) than untreated MSCs or 22Rv1-educated MSCs. While DU145 and PC3-educated MSCs showed similar levels of YKL-40, FGF-19 and IL-17 A secretion (Figs. 1a and 1b), overall the PC3-educated MSCs had the greatest response in relation to cytokine production and elevated osteopontin (OPN), IL-6, IL-8, CD105, monocyte chemotactic protein 1 (MCP-1), IL-11 and macrophage migration inhibitory factor (MIF) compared to 22Rv1-educated, DU145-educated and untreated MSCs (Figs. 1a and 1b). Cytokines and growth factors undetected are listed in Supplementary Table S1 .
Selected cytokines (OPN, IL-6 and IL-8) shown to be secreted by PC3-educated MSCs were quantitatively analysed using the MesoScale Discovery system. MSCs derived from three different donors were harvested after 10, 20 and 30 days of PC3 conditioning and placed in fresh complete medium for a further 24 hr to assess protein secretion by the PC3-educated MSCs in the absence of PC3 CM. In addition, MSCs treated for 30 days in PC3 CM were grown for an extended period in normal complete medium to assess whether any change in cytokine secretion was sustained or reversible. Donors 1 and 2 showed a consistent increase in OPN secretion in the PC3-educated MSCs at the 10-, 20-and 30-day time-points and post-conditioning. All three donor MSCs responded to the 30-day PC3 CM exposure with an increase in OPN (Fig. 1c) . PC3-educated MSCs showed a 5.6-fold (mean of three donors) increase in OPN secretion compared to untreated MSCs (p < 0.001) (Fig. 1c) .
The PC3-educated MSCs continued to secrete higher levels of OPN following extended growth in complete medium postconditioning, particularly in MSCs from donors 1 and 2 although to a lesser degree than at Day 30, maintaining a 4.3-fold (mean of three donors) increase in OPN secretion (p < 0.05) (Fig. 1c) .
Greater inter-donor variation was observed regarding IL-6 and IL-8 secretion after PC3 conditioning, reflecting the variability seen between MSCs isolated from different individuals. 15 IL-8 secretion was found to be elevated in PC3-educated MSCs in all three donors at the 10-, 20-and 30-day time-points and post-conditioning though the increase was not significant in donors 2 and 3 ( Fig. 1e) . Though there was an increase in IL-8 secretion in each PC3-educated donor post-conditioning, compared to the respective untreated control, there was an evident drop in the level of secretion compared the 30-day treated PC3-educated MSCs (Fig. 1e) . No clear trend was observed in IL-6 secretion across the three donors (Fig. 1d) . Taken together, PC3-educated MSCs were found to have the most active cytokine secretory profile compared to DU145 or 22Rv1-educated MSCs and were found to secrete an increase in IL-8 and OPN secretion following 30 days of conditioning.
Quantitative validation of growth factor secretion from PC3-educated MSCs
MSCs exposed to PC3 cell CM had the most diverse secretory profile and these cells were chosen for further validation studies. The secretion of selected growth factors VEGF, placental growth factor (PlGF), soluble fms-like tyrosine kinase-1 (sFlt-1) and FGF2 by MSCs treated for 10, 20 and 30 days was assessed compared to untreated MSCs. PC3-educated MSCs derived from donors 1 and 2 showed an increase in FGF2 secretion following 10, 20 and 30 days of conditioning, while donor 3 showed an increase only at the 10-and 20-day time-point ( Fig. 2a) . While the MSC's growth medium was supplemented with 1 ng/mL FGF2, it was not added to the medium used during any assay. Comparing the secretion levels across the three donors at the 30-day time-point, PC3-educated MSCs showed a 2.3-fold increase in FGF2 secretion 
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compared to untreated MSCs (Fig. 2a) . PC3-educated MSCs from all three donors continued secreting increased levels of FGF2 post-conditioning, with a 2.8-fold increase compared to untreated MSCs.
Decreased sFlt-1 secretion was observed from PC3-educated MSCs in all donors at the 10-, 20-and 30-day time-points ( Fig. 2b) , with a 2.4-fold decrease compared to untreated MSCs at 30 days. Donor 1 MSCs were the most responsive to PC3 CM exposure and the decrease was sustained in PC3-educated MSCs post-conditioning, while donor 3 PC3-educated MSCs were the only population not to sustain the effect (Fig. 2b) .
There was no clear trend in the increase or decrease in VEGF or PlGF secretion at any time-point (Figs. 2c and 2d) . Overall, PC3-educated MSCs secreted increased FGF2 and decreased sFlt-1 at all time-points in all donors, which was sustained post-conditioning.
Decreased expression of CAF markers in PC3-educated MSCs
MSCs have been proposed as cancer associated fibroblast (CAF) precursors and it has previously been shown that their long-term conditioning in breast and ovarian cancer cell line CM induces expression of CAF markers. 16, 17 A key question in our study was whether PC3 CM could induce a CAF-like phenotype in MSCs through upregulation of CAF-associated markers. PC3-educated MSCs were tested for the expression of CAF markers a-smooth muscle actin (aSMA), fibroblast specific-protein 1 (FSP1), fibroblast activation protein (FAP) and vimentin by immunofluorescence staining and western blotting. Transforming growth factor b (TGFb)-treated fibroblasts were included as a CAF-like myofibroblast-like positive control. In contrast to TGFb-treated fibroblasts which expressed abundant aSMA and formed stress fibres typical of CAF and myofibroblast morphology (Fig. 3a) , while MSCs expressed aSMA in both the PC3-educated and untreated MSCs, the vast majority did not form stress fibres (Fig. 3a) . Densitometry analysis of the western blot images showed that PC3-educated MSCs produced decreased aSMA in all donor cells compared to the untreated MSCs (Figs. 3b and  3d) .
FSP1 expression was barely detectable using immunofluorescence staining (Fig. 3a) and undetectable by western blot in PC3-educated MSCs and untreated MSCs (Fig. 3b) . FAP was expressed in both untreated MSCs and PC3-educated MSCs, with PC3-educated MSCs showed an increase in bright spots around the nuclei similar to TGFb-treated fibroblasts (Fig. 3a) . Finally, vimentin expression was shown to be decreased after 30 days in the PC3-educated MSCs using immunofluorescence staining and western blot (Figs. 3a and  3c) . Overall, PC3-educated MSCs do not appear to have differentiated into a traditional CAF-like phenotype but rather displayed decreased expression of Vimentin and aSMA.
PC3-educated MSCs exhibit a reversible reduction in cell migration and proliferation capacity
The impact on the migration capacity of MSCs was assessed after 10, 20 and 30 days exposure to PC3 CM. For each PC3- Figure 3 . Expression of CAF-associated markers, aSMA and vimentin, are downregulated in PC3-educated MSCs. The protein expression of CAF markers aSMA, FSP1, FAP and vimentin was assessed using immunofluorescence staining (a) and western blotting (b). Expression of aSMA was found to be decreased in PC3-educated MSCs from all donors as shown following densitometry analysis of the western blot image (b 1 d) . The expressed aSMA did not form stress fibres in the PC3-educated MSCs or untreated MSCs in comparison to the TGFbtreated fibroblasts (a). Vimentin was found to be decreased in the PC3-educated MSCs as shown from immunofluorescence staining and in all donors analysed using densitometry of the western blot image (a, b 1 c) . Images from the immunofluorescence staining are representative images taken from three-independent experiments using three separate donors.
educated MSCs donor cell migration was increased compared to the untreated MSCs following 10 days education (Figs.  4a-4c) . In contrast after 20 (Figs. 4d-4f) and 30 (Figs. 4g-4i ) days, PC3-educated MSCs, particularly donors 2 and 3, displayed decreased migration compared to untreated MSCs (Fig. 4d-4i) . Combining data from all donor MSCs the difference in the migration rate between untreated MSCs and PC3-educated MSCs was statistically significant following 10 (p < 0.0001) and 30 days (p < 0.05) of conditioning. To determine whether the inhibitory effects of PC3 CM was permanent, cells were subsequently grown for an extended period in complete medium to test whether any change in migration potential was sustained. In contrast to the 30-day conditioned MSCs, PC3-educated MSCs post-conditioning were found to migrate at an increased (donors 2 and 3) or comparable (donor 1) rate compared to the untreated MSCs (Figs. 4j-4l) . Overall, PC3-educated MSCs showed a reversible decrease in their migration following 30 days of conditioning.
Investigating the influence on MSC proliferative rates, PC3-educated MSCs treated for 10, 20 and 30 days in PC3 CM were tested for their proliferative capacity. The proliferation rate of the PC3-educated MSCs was found to be significantly decreased compared to untreated MSCs for all three donors following 10 (p < 0.001), 20 (p < 0.0001) and 30 Figure 4 . PC3-educated MSCs show a reversible decreased capacity for migration. The cell migration capacity of PC3-educated MSCs was validated using MSCs derived from three separate donors in real-time using the xCelligence system with the MSCs in serum-free medium migrating toward medium containing 10% serum. MSCs were treated for 10 (a-c), 20 (d-f) and 30 (g-i) days in PC3 CM prior to experimental use. Migration was measured by electrical impedance as the cells migrated through pores in the upper chamber of the CIM-plate and the value was given as 'cell index'. The 30-day treated cells were subsequently grown for an extended period (12-16 days) in complete medium to test whether any change in migration potential was sustained (j-l). Data represent the mean of three-technical replicates 6 SD.
(p < 0.0001) days of conditioning (Supplementary Figs. S1a-S1i). Withdrawal of PC3 CM had no effect on the proliferation rate of PC3-educated MSCs from donor 2 (Supplementary Fig. S1k ), however PC3-educated MSCs from donors 1 and 3 regained their proliferative function (Supplementary Figs. S1j and S1l).
PCa cell chemoattraction toward PC3-educated MSCs
Given that long-term treatment with PC3 CM was found to inhibit MSC migration yet induce increased secretion of chemoattractant factors including OPN and IL-8, we considered that migration of PCa cells could be more potentiated toward a monolayer of PC3-educated MSCs than untreated MSCs. Using transwell assays, tumour cells were placed in the upper chamber and allowed to migrate toward a monolayer of either untreated MSCs or PC3-educated MSCs, for 24-48 hr depending on the cell line (as illustrated in Supplementary  Fig. S2f ).
PC3 cells exhibited an increase in migration toward PC3-educated MSC monolayers from each donor compared to the untreated MSC monolayer and overall, combining data from all donor MSCs, the PC3 cells exhibited a 1.9-fold increase in migration toward the PC3-educated MSC monolayer compared to the untreated MSC monolayer (paired Student's ttest; p < 0. Fig. S2e ). These results show that PC3 but not 22Rv1 or DU145 cells migrate preferentially toward PC3-educated MSCs compared to the untreated, which suggests that PC3 CM may educate MSCs in a manner that is beneficial specifically to PC3 cells.
Comparison of migration and invasion potential of metastatic PCa-derived MSCs vs. healthy donor MSCs
To investigate the clinical relevance of our findings, we isolated primary MSCs from three patients with metastatic PCa termed MSC PCa1, MSC PCa2 and MSC PCa3. We educated the three PCa MSCs and three healthy donor MSCs (Donors 1, 4 and 5) for 30 days with PC3 and DU145 conditioned media (CM), to determine whether similar effects are observed with patient-derived MSCs. We assessed PC3 and DU145 migration toward non-educated control compared to educated MSCs at Day 30 (both PCa patient-derived MSCs and healthy donors). Figure 5a demonstrates that PC3 migration was significantly increased toward both PC3-educated MSCs and DU145-educated MSCs compared to control (p < 0.001) for all three PCa MSCs and all three healthy donor MSCs. Additionally bone metastatic PC3 migrated toward PC3-educated MSCs more than toward DU145-educated MSCs for all three PCa MSCs and two of three healthy donor MSCs. Interestingly, we also observed that PC3 had a greater affinity for the PCa patient-derived MSCs than the healthy donor MSCs. No change was observed in DU145 migration toward PC3-educated MSCs or DU145-educated healthy donor MSCs (Fig. 5b) . Alternatively, significant increases in DU145 migration were observed toward PC3-educated PCa MSCs, and toward DU145-educated PCa MSCs. In addition, we examined the invasive potential of LnCAP, DU145 and PC3 cells toward healthy MSC donor 5, and MSC PCa1 and MSC PCa2 (Fig. 5c) . Invasion of DU145 and PC3 was significantly increased toward PCa patient MSCs compared to the healthy donor MSC. LnCAP showed a non-significant increase in invasion toward MSC PCa1. Overall these results suggest that bone metastatic PC3 has an enhanced affinity for bone marrow-derived MSCs compared to the brain metastatic DU145. This is further enhanced in PCa patient-derived MSCs and after PC3 conditioning of MSCs.
Assessment of alterations in the proportion of FAP and aSMA positive cells in healthy donor and patient-derived MSCs after MSC adaption to PCa conditioning To assess if healthy donor MSC or PCa patient-derived MSC education with PC3 or DU145 CM alters CAF markers, we determined the proportion of cells expressing FAP and/or aSMA at Day 10 ( Fig. 6a-c) and Day 30 ( Fig. 6b-d) by flow cytometry. We observed reduced proportions of FAP1 aSMA1 cells after 10 days (Figure 6a ) of PC3 education of healthy donor MSCs (30.9%), compared to control (51.6%), which was maintained up to 30 days (Figure 6b ) under these conditions. Although we did not observe changes in the proportion of FAP1 aSMA1 cells after 10 days, we did observe similar reductions in FAP1 aSMA1 cells following 30-day DU145 education of healthy donor MSCs (44.6%), compared to control (60.6%). Interestingly PC3 and DU145 education of healthy donor MSCs increased the total proportion of FAP2 cells within the population at both 10 (PC3, DU145; 21.1%, 15.1%) and 30 (28.0%, 22.6%) days, compared to control at 10 (10.7%) and 30 (13.8%) days. Similar to healthy donor MSC, we observed a modest decrease in the proportion of FAP1 aSMA1 cells at both Day 10 ( Fig. 6c) and Day 30 (Fig. 6d) in PCa patient-derived MSCs educated with PC3. Alternatively, little effect was seen with DU145 education at Day 10 or Day 30. Intriguingly, PCa patient-derived MSCs had very low proportions of total FAP2 cells within the population. A slight increase in FAP2 aSMA2 cells was observed after 30 days education with PC3 or DU145, compared to control, however changes were not as dramatic as those seen in healthy donor MSCs. Supplementary Figures S3  and S4 show the levels of FAP and aSMA mean fluorescence intensity (MFI) for healthy donor and patient MSCs. We observed a trend toward reduced aSMA expression after 30 days education with PC3 or DU145. Similarly, a trend toward reduced FAP expression was seen at both 10 and 30 days. Additionally given the increased secretion of cytokines and growth factors observed previously (Fig. 1) , we examined whether PCa education of MSCs may induce cellular senescence which has previously been associated with the senescence associated secretory phenotype. Supplementary Figure S4 shows that PCa education of MSCs increases the number of b-galactosidase positive cells irrespective of whether they are derived from healthy donors of patients with metastatic PCa. Together these results suggest that PCa secretomes alter the FAP aSMA profiles of MSCs and increases the rate of cellular senescence. Future plans will explore the contributions of each FAP/aSMA subtype and their association with a SASP-MSC phenotype in the establishment of metastatic disease and disease progression.
Discussion
Tumour promoting inflammation has recently been recognised as a hallmark of cancer. 18 Tumour cells secrete cytokines, chemokines and growth factors that recruit immune cells as well as MSCs to the tumour site, and act as autocrine factors supporting cell growth. 19 This forms a dynamic microenvironment in which tumour cells interact with stromal cells to further promote tumour progression. 19, 20 To examine the interaction between bone marrowderived MSCs and PCa cells we set up an in vitro system which involved the long-term conditioning of MSCs derived from healthy male donors in PCa cell CM. We initially screened the supernatants of MSCs that were treated for 20 days in 22Rv1, DU145 and PC3 CM for the secretion of cytokines and chemokines (Fig. 1) . We found MSCs exposed to CM from the PC3 cell line had the greatest response secreting increased levels of IL-6, IL-8, CD105, MCP-1, IL-11 and MIF compared to 22Rv1-educated, DU145-educated and untreated MSCs.
Interestingly, PC3 cells are derived from bone metastases and their activity within the bone marrow microenvironment disrupts bone homeostasis, favouring bone resorption. MSCs are supportive of the HSC niche within the bone marrow microenvironment and play an integral role in maintaining bone homeostasis through the differentiation to osteoblasts. 21, 22 Therefore, cross-talk between PC3 cells and MSCs that alter MSC function could have consequences in bone remodelling. IL-8 23 and OPN 24 have been found to promote PCa progression. IL-8 has also been found to stimulate the osteoclast differentiation of osteoclast progenitors within peripheral blood mononuclear cells and human bone marrow mononuclear cell populations. 25, 26 OPN expression has been associated with osteolytic bone metastasis in breast cancer 27, 28 and has been found to mediate osteoclast anchorage to the bone mineral matrix. 29 Bone remodelling relies on a balance between bone formation and bone resorption, therefore changes in the production of factors that influence either mechanism can cause a dysregulation in bone homeostasis.
MSCs are stimulated to 'home' to injured tissue in vivo such as heart, lung, 6 liver 7 and brain 8 as well as the tumour. 5 We investigated the migration and proliferation capacity of PC3-educated MSCs following 10, 20 and 30 days of conditioning (Figs. 4 and 5 ). PC3-educated MSCs showed a reduced rate of proliferation at each time-point compared to untreated MSCs (Fig. 5) . While we found an increase in migration of PC3-educated MSCs following 10 days of conditioning, following 20 and 30 days of conditioning the migration rate was consistently decreased compared to untreated MSCs (Fig. 4) . Similarly we found that vimentin levels increased after 10 days MSC education ( Supplementary Fig. S5 ), and then decreased by 30 days, consistent with vimentins role in epithelial to mesenchymal transition. Vimentin is a Type III intermediate filament protein that is expressed in mesenchymal cells. 30 Several studies have found vimentin to have a role in cell adhesion and migration in many cell types. [30] [31] [32] [33] [34] [35] The decrease in vimentin expression might therefore explain the decrease in migration capacity found in PC3-educated MSCs. aSMA expression in fibroblasts has also been shown to correlate with increased migration and so the decrease in aSMA expression found in PC3-educated MSCs may also be causative in their decreased migration capacity. 36, 37 Both aSMA and vimentin are structural proteins and vimentin is a mesenchymal cell marker. 30, 38 Change in the expression of these factors would suggest a possible change in cell type or cellular function. Human multiple myeloma-derived MSCs have also been found to produce increased OPN compared to healthy MSCs, 39, 40 which correlates with our finding where an increase in OPN secretion was detected in PC3-educated MSCs following 30 days of conditioning compared to untreated MSCs (Fig. 1) . Although reports are conflicting 41, 42 the majority of studies have found human multiple myeloma-derived MSCs to have a decreased proliferation rate compared to healthy bone marrow-derived MSCs including an increase in senescent cells. 39, 43, 44 Furthermore, Reagan et al. found that bone marrow-derived MSCs grown in coculture with multiple myeloma cells in 3D silk scaffolds showed a decreased migration and proliferation capacity compared to when grown alone. 45 It has previously been found that long-term conditioning of MSCs in breast cancer and ovarian cancer CM resulted in the transition of MSCs to CAFs. 16, 17 It was therefore a relevant question to ask whether PC3-educated MSCs could be characterised as CAFs. To test this, we looked at protein expression of CAF markers aSMA, FSP1, FAP and vimentin. We found that rather than an increase in the expression of CAF markers the PC3-educated MSCs expressed decreased vimentin and aSMA protein, and had a reduced proportion of FAP1 aSMA1 cells. Similar effects were seen with patient-derived MSCs. The transition from an MSC to a CAF observed in the literature 16, 17, 46, 47 could be dependent on the specific tumour cell type and the level of exposure to key factors such as TGFb in the culture conditions or in vivo tumour microenvironment. Importantly we observed an increase in senescent cells after PC3 or DU145 conditioning in both healthy donor MSCs and PCa patient derived MSC, indicating that a senescent MSC phenotype may also contribute to our findings. PC3-educated MSCs displayed a unique, secretory profile compared to 22Rv1-educated, DU145-educated and untreated MSCs, which suggests a conditioning response specific to tumour cell type. We investigated the migration of 22Rv1, DU145 and PC3 cells toward a monolayer of untreated MSCs or PC3-educated MSCs (Fig. 6) . We found that 22Rv1 cells were not stimulated to migrate toward either untreated MSCs or PC3-educated MSCs. DU145 cells migrated toward both untreated MSCs and PC3-educated monolayers to a similar degree. We did however find a 1.9-fold increase in PC3 cell migration toward the PC3-educated MSCs compared to untreated MSCs. Of further interest, we found that PCa patient bone marrow-derived MSCs exhibited a greater chemoattraction potential than healthy donor MSCs. This could be further increased again with PC3 conditioning.
The 'seed' and 'soil' hypothesis, initially described by Paget in 1889, proposes the idea that the tumour cell migrates to specific tissues based on favourable interactions with the given secondary site. 48 The theory has since been developed to suggest that circulating factors released by the primary tumour interact with cells of the secondary site, in this case the bone marrow, to create a 'pre-metastatic' niche that stimulates chemotaxis of the metastatic tumour cells to a favourable microenvironment. 49, 50 Based on our research it could be proposed that factors released by metastatic PCa cells educate bone marrow resident MSCs to secrete chemoattractant factors, potentially via SASP mechanisms, that enhance migration toward the bone while also preventing their migration away from the bone.
Conclusions
PCa, when it metastasises, is almost unique in its predilection for the bony skeleton, as opposed to soft tissue sites. 2 Our work described here, may help elucidate a mechanism, which could explain this clinical fact. In our study, we found that MSCs treated for 30 days with PC3 CM secreted increased levels of the pro-tumourigenic factors -IL-8, OPN and FGF2 -and decreased sFlt-1 compared to untreated MSCs, which was sustained following extended culture in normal growth medium. The migration and proliferation capacity of MSCs was reversibly inhibited following 20 and 30 days of conditioning. PC3-educated MSCs were not found to express an increase in CAF-associated markers. PC3 cells, but not DU145 or 22Rv1 cells exhibited increased migration toward PC3-educated MSCs compared to untreated MSCs. Therefore, PC3 CM induces an 'activated' phenotype in MSCs that is specific to PC3 cell conditioning. This is further supported by our findings that MSCs derived from metastatic PCa patients, show significantly increased chemoattraction for PCa cells, in particular bone metastasis-derived PC3. What drives cancer cells from a given tissue to preferentially home to a particular secondary site remains elusive. Our research could therefore shed light on how tumour cells can educate its surrounding microenvironment or the microenvironment of the landing metastatic cell to specifically lure circulating tumour cells and further cancer development.
